Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systemic and Topical Geroprotective Rejuvenation Assessed by START/REST Aging Clocks
NCT07888595Phase 1Enrolling by invitation
- Sponsor
- Frontiers in Bioscience Research Institute in Aging and Cancer
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of liquid metformin (Aspargo Labs), chloroquine, CHILD-IVITAB, thymoquinone and UROLITINN in aging, sponsored by Frontiers in Bioscience Research Institute in Aging and Cancer. Primary endpoint: START/REST biological age (transcriptomic tAge and proteomic pAge) at 4 weeks. Started Oct 2026; status: enrolling by invitation.
02
Drugs
liquid metformin (Aspargo Labs)chloroquineCHILD-IVITABthymoquinoneUROLITINN
03
Conditions
aging
Beyond the preview
Go deeper on NCT07888595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07888595.